سعر تافانيك 250مجم 5 اقراص 2022

Levofloxacin 250 mg film-coated tablets (fluoroquinolone antibacterial), pack of 5.

• US label (250 mg-relevant uses): complicated urinary tract infections and acute pyelonephritis (250 mg once daily for 10 days), uncomplicated urinary tract infection (250 mg once daily for 3 days); the 250 mg tablet is also used for renal dose adjustment and for pediatric inhalational anthrax/plague dosing (250 mg every 12 h for patients 30 to <50 kg).Population: AdultsDailyMed (U.S. National Library of Medicine)

• Most common (>=3%): nausea, headache, diarrhea, insomnia, constipation and dizziness.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Known hypersensitivity to levofloxacin or other quinolone antibacterials.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning: disabling and potentially irreversible serious adverse reactions (tendinitis/tendon rupture, peripheral neuropathy, CNS effects) and exacerbation of myasthenia gravis; reserve for patients without alternatives in acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis and uncomplicated UTI.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Serious, occasionally fatal anaphylactic and skin reactions; severe hepatotoxicity; Clostridioides difficile-associated diarrhoea; hematologic and renal toxicities.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Published case reports and observational studies have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Breastfeeding not recommended during treatment; a lactating woman may pump and discard milk during treatment and for 2 additional days after the last dose.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Levofloxacin: Levofloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes needed for bacterial DNA replication (WHO ATC fluoroquinolone; US label section 12.1).